Mary Eileen Dolan to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Mary Eileen Dolan has written about Leukemia, Myeloid, Acute.
Connection Strength
0.767
-
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23; 121(21):4366-76.
Score: 0.290
-
Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2020 06 15; 26(12):2891-2897.
Score: 0.117
-
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66.
Score: 0.075
-
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23.
Score: 0.064
-
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
Score: 0.063
-
Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009 Apr 01; 23(7):877-89.
Score: 0.055
-
Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Clin Pharmacol Ther. 2008 Dec; 84(6):691-7.
Score: 0.052
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.051